Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Data ReadoutpositiveCARVYKTIPositive

AI Analysis

Summary

Legend Biotech presented five-year follow-up data for CARVYKTI in relapsed or refractory multiple myeloma, showing 50% of patients remained progression-free and alive at five years with a 69.2% overall survival rate following a single infusion.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Five-year progression-free survival rate of 50%, five-year overall survival rate of 69.2%

Importance:7/10

Sentiment:

0.85

CARVYKTImultiple myelomalong-term dataCAR-T5-year follow-up

Related Companies

$LEGN

Read the original article

Published by GlobeNewswire Clinical Studies on September 25, 2026 11:00 AM

Read Original